text:
2Honors
2.1Champions
3Players
3.1Current roster
3.2Honored members
3.3NHL alumni
Ice hockey team in Bern, Switzerland
Home arena
PostFinance Arena
Marc Lüthi
Andrew Ebbett
Johan Lundskog
Simon Moser
EHC Visp
www.scb.ch
Schlittschuh Club Bern (Ice-skating Club Bern in English) is an ice hockey team based in Bern, Switzerland. They play in the National League (NL), the top tier of the Swiss hockey league system. For the 18th year in a row, the club is the most attended ice hockey team in Europe for the 2018–19 regular season, averaging 16,290 spectators.[1]
They are traditional rivals with HC Fribourg-Gottéron, EHC Biel, and the SCL Tigers.
SC Bern versus SCL Tigers in an outdoor game 14 January 2007.
The ice hockey section of the Bern Sports Club, which was established on 3 November 1930, officially began playing on 1 January 1931.
Today, SC Bern is a highly popular team and regularly fills its home stadium, the PostFinance Arena, one of the largest ice hockey stadiums in Europe. In 2006, they set a new record among European clubs for average attendance, with an average of 15,994 in 22 home games.[2] They have won the Swiss Championship thirteen times, with the most famous victory coming in 1989 over HC Lugano
During the 2004–05 NHL lockout, Daniel Brière, Dany Heatley, J. P. Dumont, Marc Savard, Henrik Tallinder, and Chris Clark played for SC Bern. Although, league rules allow only four players without Swiss passports to suit up in a single game.
After a disappointing run in the 2006 playoffs, the club replaced head coach Alpo Suhonen with John Van Boxmeer and general manager Roberto Triulzi with Sven Leuenberger.[3] Leuenberger had previously played thirteen seasons of defence with the club, totaling 67 goals, 145 assists, and four national championships. His jersey number 16 is one of many that has been retired by SC Bern.
On 30 September 2008, SC Bern faced off against the National Hockey League's New York Rangers to celebrate one hundred years of ice hockey in Switzerland. Forty-nine years since the Rangers' last visit to Switzerland, the blueshirts beat the home team 8–1 in front of a sellout crowd. Despite the slanted score, SC Bern played a close game with a 2–0 score at the end of the second. Former Phoenix Coyotes' Canadian-born defenceman Travis Roche scored SC Bern's goal early in the third period, bringing the game to 2–1. SC Bern only allowed two even-strength goals, but could not withstand the Rangers' potent power play in the final frame (6-for-9). "We played for our pride tonight," said center Sébastien Bordeleau after the exhibition game. Christian Dubé wore the captain's "C" because Ivo Rüthemann was injured.
During the 2012 NHL lockout, Roman Josi, Mark Streit and John Tavares played for the SC Bern. Tavares quickly became the PostFinance Top Scorer tallying 42 points (17G, 25A) in 28 games.
During the 2013–14 season, Guy Boucher signed a contract as coach of the SC Bern for the current year and two more seasons. He has since been relieved from his duties, moving on to coach the Ottawa Senators, being replaced by former assistant and SC Bern player Lars Leuenberger, who guided the team to the championship in 2016. Leuenberger was then replaced by former Finnish national team coach Kari Jalonen prior to the 2016–17 season. Jalonen went on to win the NL title in his first year at the helm of the team.
On 1 October 2018, SC Bern played a friendly game against the New Jersey Devils of the National Hockey League (NHL), which featured their former player Nico Hischier who in 2017 became the first Swiss player to be drafted first overall in an NHL Entry Draft.[4][5]
On January 28, 2020, Jalonen was relieved of his duties following terrible results. Hans Kossmann stepped in to replace him as head coach for the remainder of the 2019/20 season.
Honors[edit]
Champions[edit]
NL Championship (16): 1959, 1965, 1974, 1975, 1977, 1979, 1989, 1991, 1992, 1997, 2004, 2010, 2013, 2016, 2017, 2019
SL Championship (3): 1958, 1969, 1972
Swiss Cup (3): 1965, 2015, 2021
European Cup appearances (10): 1965, 1974, 1975, 1977, 1979, 1989, 1991, 1992, 1996, 1997
Players[edit]
Current roster[edit]
Updated 27 March 2022.[6]
D R 28 2016 Malmö, Sweden
Thierry Bader
C L 25 2020 Winterthur, Switzerland
Alain Berger
RW L 32 2012 Burgdorf, Switzerland
Eric Blum
D L 36 2014 Pfaffnau, Switzerland
Ronny Dähler
C L 21 2020 Bern, Switzerland
Kaspars Daugavins
C L 34 2021 Riga, Latvia
Joshua Fahrni
C R 20 2020 Switzerland
Éric Gélinas
D L 31 2022 Vanier, Ontario, Canada
Beat Gerber
D L 40 2003 Oberlangenegg, Switzerland
Colin Gerber
D L 24 2017 Switzerland
Cody Goloubef
D R 33 2022 Oakville, Ontario, Canada
Mika Henauer
D L 22 2019 Zurich, Switzerland
Dustin Jeffrey
LW L 34 2020 Sarnia, Ontario, Canada
Dominik Kahun
C L 27 2021 Planá, Czech Republic
Timothy Kast
C L 34 2021 Genève, Switzerland
Daniel Manzato
G L 39 2021 Fribourg, Switzerland
Nick Meile
D L 18 2021 Wolfwil, Switzerland
Simon Moser (C)
F L 33 2013 Bern, Switzerland
Santiago Näf
F R 20 2020 Switzerland
Christian Pinana
D L 25 2021 Bellinzona, Switzerland
Thomas Rufenacht
W L 37 2014 Meggen, Switzerland
Tristan Scherwey (A)
W L 31 2009 Wünnewil-Flamatt, Switzerland
Tristan Wells
G R 69 2018 Berlin, Germany
Christian Thomas
RW R 30 2021 Toronto, Ontario, Canada
Ramon Untersander (A)
D R 32 2015 Alt St. Johann, Switzerland
Phil Varone
C L 32 2021 Vaughan, Ontario, Canada
Joel Vermin
LW L 30 2022 Frauenkappelen, Switzerland
G L 25 2020 Bern, Switzerland
Honored members[edit]
0 René Kiener
6 Peter Stammbach, number retired on 1 December 2009
7 Martin Rauch
12 Roland Dellsberger
16 Sven Leuenberger
18 Renzo Holzer, number retired on 1 December 2009
22 Patrick Howald, number retired on 1 December 2009
31 Renato Tosio
32 Ivo Rüthemann, number retired 15 November 2014
NHL alumni[edit]
Bryan Lefley (1980–1982)
Claude Noël (1981–1982)
Peter Sullivan (1983–1984)
Gaston Therrien (1984–1986)
Kirk Bowman (1984–1988)
Reijo Ruotsalainen (1986–1987, 1988–1989, 1990–1992)
Risto Siltanen (1987–1988)
Alan Haworth (1988–1992)
Paul Boutilier (1989–1990)
Kevin LaVallee (1989–1990)
Marc Habscheid (1992–1993)
Dan Quinn (1993–1994)
Raimo Summanen (1993–1994)
Gaetano Orlando (1994–1998)
Ville Sirén (1995–1998)
Timo Jutila (1996–1997)
Daniel Marois (1996–1999)
Mike Donnelly (1997–1998)
David Sacco (1997–1998)
Alexander Godynyuk (1998–1999)
Dave McLlwain (1998–2000)
Patrik Juhlin (1999–2005)
Andreas Johansson (2000–2001)
Fredrik Olausson (2000–2001)
Ryan Savoia (2000–2001)
Derek Armstrong (2001–2002)
Claude Vilgrain (2001–2002)
Thomas Ziegler (2001–2010)
Yves Sarault (2002–2005)
Sébastien Bordeleau (2002–2009)
Christian Dubé (2002–2011)
Sylvain Lefebvre (2003–2004)
Rich Brennan (2004–2005)
Daniel Brière (2004–2005)
Chris Clark (2004–2005)
Dany Heatley (2004–2005)
Marc Savard (2004–2005)
Henrik Tallinder (2004–2005)
J. P. Dumont (2004–2005, 2011–2012)
Éric Perrin (2005–2006)
Pascal Trépanier (2005–2006)
Éric Landry (2006–2007)
Claude Lapointe (2006–2007)
Christian Berglund (2006–2008)
Simon Gamache (2006–2011)
Roman Josi (2006–2010, 2012–2013)
Patrik Štefan (2007)
Nathan Dempsey (2007–2008)
Mark Mowers (2007–2008)
Ramzi Abid (2007–2009)
Keith Carney (2008–2009)
Martin Gélinas (2008–2009)
Travis Roche (2008–2014)
Ľuboš Bartečko (2009–2010)
Lee Goren (2009–2011)
Brett McLean (2009–2011)
Jean-Pierre Vigier (2009–2012)
Joël Vermin (2009–2014)
Joel Kwiatkowski (2010–2012)
Geoff Kinrade (2011–2014)
Christoph Bertschy (2011–2015)
Byron Ritchie (2011–2017)
Jaroslav Bednář (2012–2013)
Mark Streit (2012–2013)
Petr Sýkora (2012–2013)
John Tavares (2012–2013)
Hnat Domenichelli (2013–2014)
Mikko Lehtonen (2013–2014)
Glen Metropolit (2013–2014)
Rostislav Olesz (2013–2014)
Marc-André Gragnani (2014–2015)
Bud Holloway (2014–2015)
Jesse Joensuu (2014–2015)
Nolan Schaefer (2014–2015)
Chuck Kobasew (2014–2016)
Simon Moser (2014–present)
Sean Bergenheim (2015–2016)
Cory Conacher (2015–2016)
Timo Helbling (2015–2016)
Nico Hischier (2015–2016)
Derek Roy (2015–2016)
Trevor Smith (2015–2016)
Andrew Ebbett (2015–2020)
Aaron Gagnon (2016–2017)
Maxime Macenauer (2016–2017)
Maxim Noreau (2016–2018)
Mark Arcobello (2016–2020)
Jeremy Morin (2017–2018)
Mika Pyörälä (2017–2018)
Mason Raymond (2017–2018)
Gaetan Haas (2017–2020)
Adam Almquist (2018–2019)
Jan Muršak (2018–2020)
Christian Thomas (2020–2020)
Dustin Jeffrey (2020–present)
Category:SC Bern players
Category:SC Bern coaches
^ "European attendance ranking". www.iihf.com. Retrieved 30 December 2019.
^ "Iihf - News". Archived from the original on 19 March 2006. Retrieved 16 March 2006.
^ "Bear season over in Switzerland". www.iihf.com. 14 March 2008. Archived from the original on 6 April 2012. Retrieved 4 August 2010.
^ Morreale, Mike G. (1 October 2018). "Hall scores in overtime to give Devils victory against SC Bern". NHL.com. Retrieved 2 October 2018.
^ Morreale, Mike G. (1 October 2018). "Hischier gives fans night to remember in Switzerland". NHL.com. Retrieved 2 October 2018. The 19-year-old was selected No. 1 in the 2017 NHL Draft, the only Switzerland-born player be chosen No. 1.
^ "SC Bern current roster". www.scb.ch (in German). Retrieved 19 March 2022.
Official website (in German)
Meltzer, Bill "Swiss Playoffs: SC Bern Prowling for Gold" at NHL.com Retrieved 21 March 2007
HC Ajoie
HC Ambrì-Piotta
HC Fribourg-Gottéron
Genève-Servette HC
List of NLA seasons
Spengler Cup
Ice hockey in Switzerland
See also: IIHF
IIHF Continental Cup
IIHF European Champions Cup
Retrieved from "https://en.wikipedia.org/w/index.php?title=SC_Bern&oldid=1130570110"
Ice hockey teams in Switzerland
Sport in Bern
Ice hockey clubs established in 1930
CS1 German-language sources (de)
Articles with German-language sources (de)


text:
Chris Gunter
Gunter (Texas)

Desambiguação

redpajama_set_name: RedPajamaWikipedia


text:
HUL making friends for Sure
By Poojya Trivedi , afaqs!, New Delhi | In Advertising
The company initiated a BTL activity for its antiperspirant, Sure. Through this initiative, about 30,000 students have registered on ground as Sure trainers.
In order to promote its antiperspirant brand, Sure, Hindustan Unilever (HUL), in association with Candid Marketing, conducted a college contact programme called Friends of Sure (FOS). The initiative used word-of-mouth to publicise the product.
The initiative focussed on educating young Indian women on hygiene through the use of antiperspirants and how they work to deliver underarm dryness or 'No Paseena' - the brand's tagline.
Devika Sharma, vice-president, client servicing, Candid Marketing, says, "In our country, antiperspirants are an untapped category. In order to reach out to the target audience and get the functional benefit of the product across, education was the key objective. The programme thus focussed on spending quality time with the audience in a controlled environment to get the message across."
She adds that the antiperspirant market in India is highly underdeveloped and through this programme, the aim was to develop the antiperspirant category.
As part of the activity, the campaign was carried out in 16 cities, including Mumbai, Pune, Nasik, Nagpur, Baroda, Ahmedabad, Bengaluru, Hyderabad, Chennai, Manipal, Coimbatore, Delhi, Ludhiana, Chandigrah, Jalandhar and Kolkata. Female students from 150 colleges were invited to join the programme and participate as Sure Friends or trainers. They were to inform other women about the hygiene benefits of using antiperspirants as opposed to regular deodorants or talc, which only mask body odour.
These trainers were to encourage other young women to participate in the programme and tell their friends about Sure by downloading the FOS mobile application.
"We chose to use word-of-mouth as a medium to spread awareness by getting converts to convert their peers - in order to fast track trials. Also, antiperspirant products are hygiene products, not the easiest topic to talk about with strangers. Hence, peer-to-peer marketing was the most suitable option," says Sharma.
The top 20 Sure Friends will be awarded cash scholarships worth a lakh each in the first half of 2011. Numerous other prizes such as laptops, mobile phones, free talk-time, movie vouchers and gift hampers are also being given out.
Through this initiative, about 30,000 students have registered on ground as Sure trainers.
The company initially conducted a pilot programme with 16 college girls from Mumbai and these girls went across the country to conduct the sessions and narrate their experiences with the programme.
The sessions in the college were divided into four segments: tips on hygiene, health, grooming and beauty, and time management. Sharma says, "The sessions were positioned more as a hygiene and self confidence boosting mission to show students how participating in this programme will help them in their holistic development, assist them in their future career and life in general."
HUL launched Sure in the Indian market last summer. The product claims to be the largest selling antiperspirant brand in the world. Sure is sold extensively in the UK and Europe. HUL has roped in Bollywood actor Asin for the promotion of Sure.
HUL
Candid Marketing
below-the-line
Knorr Soupy Noodles: Testing the fun quotient
HUL hands over OOH duties to Lintas Media Group
Lux ropes in Asin as brand ambassador for natural variant
Candid Marketing undergoes revamping; changes logo

redpajama_set_name: RedPajamaCommonCrawl


THA209G (1969) Bedford VAL70 . Duple (Northern) Viceroy 37 C53F. Ex-Mann . Smethwick . Seen 1991 Hants. It had previously been owned by Chris & Zoe , then Scouse Steve , Iain sold it back to Chris & Zoe & then it passed to Tim & finally Handbag Steve , before Danny weighed it in at Tywford Wood site . Photo = Taff .


This section serves as an online repository of material produced by us for our customers and partners. Information about Polaris Net, our products and services, and our customer success stories can be found here.
Polaris Customer Relationship Management (CRM) - "Helping Create Higher-Value Relationships with Your Customers"
Supportworks ESP Service Desk - "Integrated Solution for IT Service Management and Business Process Support"
Customer Relationship Management (CRM) - "What Is It and Why Do It?


text:
Kelsea Ballerini Is 'Honest' About Growing Up on New Album
Christopher Polk, Getty Images
Kelsea Ballerini will soon release her sophomore studio album, and fans can expect to hear a more mature side and pop sound from the country starlet.
In an interview with GQ, Ballerini opens up about the direction her sophomore album is moving in and how she's grown since her breakthrough project, The First Time. She admits that the new record shows off her growth over the past few years.
"I have to be honest about growing up and becoming a young woman. That's why we picked 'Yeah Boy' to be the last single from the first album—there's nothing like that on this next record," Ballerini says.
While the yet-to-be-released project shows off a new facet of the star, she assures that her young audience will still be able to identify with her like they did when she first launched onto the country music scene in 2015. "The whole heartbeat of the first record is young, which I think is what made it relatable to young girls. Which was a really special thing," the "Peter Pan" singer explains. "And so I'm careful to acknowledge that when I'm writing now. I still want to keep those young girls that liked that version of my music."
Ballerini is currently one of the opening acts on Thomas Rhett's 2017 Home Team Tour that crosses the U.S. and Canada throughout the spring and summer. Rhett and crew will also make several stops in the United Kingdom in England, Scotland and Ireland. Ryan Hurd and Russell Dickerson are also a part of the tour as supporting acts.
Women Who Are Changing Modern Country Music
Next: Kelsea Ballerini Takes Being a Role Model to Heart
Source: Kelsea Ballerini Is 'Honest' About Growing Up on New Album
Filed Under: kelsea ballerini


Peachy Keen Challenge #66 AND Cake Pop Video!
Peachy Keen Kut Outs Blog Hop!
Gift Tag w/the new Tim Holtz Winter Edition ink!
Meet "My Creative Time's" new design team!
Welcome to another Throwback Thursday Challenge!
This is one week before My Creative Time's November Stamp Release happening next Friday, Nov. 18th @ 12:01am! So, you know what that means.... right? That means if you participate in this challenge, you will have the "Golden opportunity" to qualify to win the ENTIRE release next week! This is probably the BEST release to date!;) The deadline for this challenge will be on Wed, Nov. 16th! So you only have one week to complete your projects in order to qualify!
***MUST BE A "Kid Friendly" THEME project of YOUR choice!!!
*** Deadline for this challenge will be on Wed, Nov 16th @ midnight!
Here is a quick little video for ya!
Here is Miss Leanne's CUTIE PATOOTIE card using my "Turn That Frown Upside Down" stamp set!
Here is Miss Liz's SUPER FUN card using my "Wow, So Many Candles" stamp set!
Miss Linsey made this SUPER SWEET card using "All Around Birthday Time", "All Around Accessories" stamp sets along w/the "Scallop & Stitch Circle Die" set!
Sweet, I think I should try this throw Back Thursday..... Would be fab. to win! Great projects, you have a great DT! TFS!
Is she the cutest!!!! Absolutely adorable card. Love the colors. I also LOVE all your DT's projects. Thank you so much for sharing.
That is one cute little girl! Can't wait to make my card!! Great inspiration from the DT!
sooo cuuute emma! I need those doggie faces!!! :) everyone did such a fab job!
I love the stamp set. I'm getting excited for this stamp release if they are all as cute as that one. I can't wait to play along today!!
What a fun challenge today! Everybody's projects are so cute!!! Emma, the details on your little girl and her dog are just perfect! Love it!
LOVE, LOVE the cards!! Great stamp sets.
This one is one my favorite cards you have made! So super cute:) I love it!!!
Love your card with the little doggie! Also loved the wreath you made the other day.
I just entered this challenge and so excited for the chance to win your awesome stamps!
Your card is soooo cute!!! I have the Playtime cart and I don't remember that cut. I LOVE it!
I LOVE that 'bow'. Pink and sparkly - now that's MY kind of bow!
Love this Emma! You're such an enabler. Now I think I need to get some Peachy Keen faces!
Your card is so super adorable!! and the DT did a fab job as always!!
I LOVE your card,Emma!!! SOOO cute! I just LOVE the colors,the cute little girl and the ribbon!! SO pretty!!!
Oh my goodness,these are adorable!! Great job everyone!!! Love them all!!
Love all the cute stuff. Thanks for the challenge.
AW Emma, your card is so darling, the little girl and dog are adorable. Love the bow, I will have to give that a try. Your Design Team did an amazing job as always.
Super Cute card Emma....love that face!! Your DT did a awesome job!!
What fabulous cards and such a fun challenge! Thanks Emma!
Great projects, thanks for the fun challenge!
What an adorable card Emma!! I think I may need to pull out that cartridge! Fabulous job!!
you and your DT did an amazing job!
Great challenge! Love all the projects and looking forward to your sneak peaks.
Great challenge. I'm so glad I had some time to participate in this one! I can not wait until next week!!
Sweet card...sure to get a smile or two with this card.
Love the details! Awesome card! OK< so I am trying the Throwback Thursday Challenge! Hope you enjoy!
Like the creations. Entered a Book Scrapbook Layout in which I used "Kid Friendly" Cricut cartridge Locker Talk Bookstack for a "Kid Freindly" theme of my daughter reading Harry Potter book.
Your DT did a great job, as always. Thanks for the challenge. I'm glad I had the time to join this one.
Thanks Emma! Another amazing card!
I enjoy the challenge because it makes me thinking about what color, image, or shapes are needed to make my own card. It takes a little time but to finish it is awesome. Thanks for the opportunity for the challenge!
Thank you for hosting this challenge! It always so much fun to play along! Your card is adorable! I also want to thank you for all you do on your blog. You inspire me and I always enjoy viewing your projects and watching your videos. You are very talented.
Super cute card Miss Emma! I love the added touch of the Peachy Keen Stamps.
Super fun Challenge Emma. Thank you for putting it on.
Great cards from everyone, they are all so cute.
All of the design team cards are sooo adorable. Thanks for all the inspiration and for another great challenge.
Yay! I just finished up my card and entered it here. Thank you for this fun challenge!
Everyone has made some fun and inspirational projects. I loved this challenge. It was so much fun to do. Thanks for the chance.
Great challenge! It gave me a chance to finish a project I started 5 months ago!
Love this challenge! All of the projects are amazing!
Love your blog and all your card ideas.
Your card is so cute. I had so much fun with this challenge. It's been a very trying week and I so needed to have some fun creating a very fun project. Thanks for challenging me!
This is the first time I have been to your site and I found it via Creative Diva. I love this challenge and I just recently did a very "kid freindly project" so how cool is that for timing? I love your stamps. I am super excited I found you!
Absolutely love your stamps! Can not wait to the new release because I am always looking to update.
What a great card Emma!! :) I just linked mine up!! Thanks for the really fun Challenge! :)So excited it's release week!!!
WOW what fabulous projects. Thank you for a fun challenge! I had a blast!
Love everyone's great cards. Great work new design team.
Adorable card! And the DT did an excellent job! Awesome! Had so much fun with the challenge! Thanks for inspiring us Emma!
Love the card! Those doggie faces are on my wish list. Thanks for making me dig out my Baby Steps to play along with!
I can't wait to see your new release.
YAY!!! So glad I got my challenge entry in for a chance to win your new release!!! Thanks for such a fun challenge!
Perfect challenge for me because I just got the "B" is for Boy cart and I love it. Thanks for the fun challenge.
Just an absolutely adorable card Emma! The DT is AMAZING! Every project is superb!
Thanks for the fun challenge and a chance to win a fabulous set of stamps.
Your card is sooo cute! I am going to try to do one of those bows someday. I have some buckles like the one you used with your bow and was wondering what I could use them for. Now I know.(Saw them on clearance at Walmart and just had to get them. Lol.) Thank you for the challenge and the opportunity to win. This is my first time trying the challenge.
Can't wait to see your full release on Friday.
Wow 69 entries before me.
Having a sports oriented family, I'm real excited about this newest release. The DT did a fantastic job, as always.
Love your card Emma.I'm a last minute entry as the card is for my son's birthday and didn't want to post the picture before he had opened his card!
Whoops I linked twice, silly lag, sorry about that!
Emma Thanks for the wonderful and fun challenge. I would love to win your stamp set.
I love all the great cards and thanks for all the fun. Your challenges are great.
Thank you for the challenge. I love all of the cards.
This is my first try at your challenge and also at doing a wiper card. It was lots of fun and love the new stamp sets too!
Love all of the DT entries and as always your card is Awesome!! I love seeing what you come up with for each challenge. Decided this challenge was just the thing to get me to try making a new style of card. Thanks for the "push" lol.
I thought I did this, but for some reason my link wasn't showing. I'm glad I checked back. Loving your newest release. You go Emma!


text:
JRPGs
Bandai Namco's 2016 slate revamps Japanese games for the west
By Matt Kamen
Gallery: Bandai Namco's 2016 slate revamps Japanese games for the west
Japanese game publisher Bandai Namco is gearing up for a massive global push in 2016, with a host of original titles and anime properties making a western appearance.
As part of the Jump Festa event in Tokyo, Japan, the company highlighted games coming to console, mobile, and PC, and its plans to introduce western players to some of Japan's most popular franchises, including Gundam, God Eater, One Piece, and Naruto.
One of the biggest new titles will be God Eater, an action title with shades of Monster Hunter, but with a much stronger emphasis on story. Set in a world where biotech monsters known as Aragami run amok, players control the newest recruit in an organisation dedicated to their destruction.
In order to see this embed, you must give consent to Social Media cookies. Open my cookie preferences.
Final Fantasy announces 30th anniversary event with games, DLC...and wine
Although God Eater debuted on PSP in 2010, next year's release is the start of a relaunch for the series. Bandai Namco is bringing over both God Eater: Resurrection (a PS4 remake of the first game that massively expands on its handheld roots) and God Eater 2: Rage Burst, with releases planned for PS4, PS Vita, and PC. Exact release dates are still to be confirmed, but are planned to launch in "close succession" next summer. The games' launch follows the God Eater anime, which is streaming internationally now, and tells an original story in the same universe.
Gameplay is centred on real-time battles against the colossal Aragami, with teams of heroes using advanced weapons called "God Arts" to slay them. Switching between sword and gun modes allows for melee and ranged attacks, while co-op play (or team commands when solo) add strategy and teamwork. There are differences in the battle system for each game though; while Resurrection favours consuming downed enemies to power up, Rage Burst introduces a "Blood Arts" system, where successive attacks unlocks powerful special moves, making combat faster and more stylish. Already a hit in Japan with over 3m units sold, the cross-media focus and accessible yet deep combat of the games position this as potentially Bandai Namco's next big franchise.
Further original titles planned for the year ahead include the already announced Ace Combat 7, a return of the combat flight simulator series, and fighting series Tekken 7, which sees Street Fighter's Akuma as a guest combatant -- both titles now boasting PlayStation VR support too -- and the long-awaited Ni no Kuni II, a sequel to Level-5's beautiful RPG. Tales of Berseria, the next instalment in Bandai Namco's own anime-inspired RPG series, was also shown at Jump Festa. The game, set for PS4 and PC (a planned PS3 release seems to have been abandoned, at least for Europe and the US), features the series' first solo female protagonist, and has a pirate theme. Bandai Namco will be revealing more details on all these titles early in 2016.
Bandai Namco is also expanding its mobile gaming presence, with announcement of Tap My Katamari, a title the company had registered domain names for recently but not confirmed. The release will bring the colourful, strange puzzle series onto smartphone and tablet platforms.
The zany games have traditionally seen players rolling up objects into a rapidly expanding sphere, growing from a few centimetres in diameter to scooping up entire planets as you go. Quite how this will work on mobile remains to be seen -- the console versions relied heavily on dual-thumbstick controls, for instance -- but the series has a dedicated fanbase that will be eager to find out. What is known is that it will have a Time Attack mode, similar to some console iterations, feature 35 recruitable "cousins" offering new powers and abilities, and support offline play. Set to launch for Android and iOS in early 2016, it joins the successful Pac-Man 256 -- an endless runner twist on the classic arcade game which has racked up over 16m downloads and just launched on Apple TV -- and Digimon Heroes, a card-based monster battling game also set for Android and iOS later in 2016.
Tales of Berseria review: this tale of rage and pain sets the bar high for JRPGs
Fans of anime will likely be pleased by the 2016 line-up. The year kicks off with a double-header on 5 February, with the launch of both Naruto Shippuden: Ultimate Ninja Storm 4 and Digimon Stories: Cyber Sleuth.
The former, based on the final storyarc of Masashi Kishimoto's manga about super-powered ninja, will be the final Ninja Storm game. However, as the first developed with PS4 and Xbox One in mind, it sees the series go out with a bang. Producer Miho Nakagawa told WIRED that the more powerful hardware allowed for battles featuring up to six characters, destructible environments, and a huge leap in animation quality -- Nakagawa said "it changes from TV animation quality to animation in the theatre; it's that much of a difference on this system's power." It will also feature over 100 playable characters from the Naruto universe, and huge story-driven boss battles peppered through its single player campaign.
Digimon Stories: Cyber Sleuth, meanwhile, brings back the "other" virtual monster series from the 1990s. While Pokemon was the greater success, Digimon enjoys a loyal following still, and the new game has grown up with that original audience. The new game -- which is coming to PS4 and Vita in the west largely as the result of fan petitions demanding it -- delivers a "traditional" turn-based RPG with a deeper story than casual observers might expect. With the lines between the human and Digimon worlds blurring, tears in reality are opening across Tokyo. Players can team with hundreds of powerful creatures, forming parties to explore the disturbances. A "Digimon Farm" mode harkens back to the series' Tamagotchi roots, allowing you to raise and train your monsters before taking them into the field.
Bandai Namco follows up with One Piece: Burning Blood in June (date TBC), adapting the most recent arc of Eiichiro Oda's pirate action manga into a one-on-one fighting game. After several Dynasty Warriors-style spin-offs, this is shaping up to be something of a return to form for the series, with dozens of playable characters each boasting a range of unique abilities. Expect huge, arena-shaking battles and anime-authentic graphics when this launches on PS4, PS Vita, PC, and -- for the first time in the series' history -- Xbox One.
Later in summer 2016, JoJo's Bizarre Adventure: Eyes of Heaven arrives on PS4. A fighting game sequel to last year's All-Star Battle, the new entry opts for two-on-two battles and a story mode overseen by Hirohiko Araki, creator of the original manga.
A generational saga, JoJo's lives up to its "bizarre" moniker. It follows members of the Joestar family as they're drawn into battles against the likes of vampires, Mayan deities, and an evil President of the US in an alternate timeline, while using giant avatars known as Stands to fight. While not yet a breakout success in the west, the series has rapidly grown in popularity outside of Japan since the ongoing anime series launched. The new game capitalises on that, offering a crossover adventure with all eight generations and a roster of more than 50 characters.
Finally, Bandai Namco is planning a wider push for the Gundam franchise, across anime and gaming properties. Mobile Suit Gundam: Extreme VS Force will be a Vita-exclusive title, with a hybrid experience of turn-based strategy and two-on-two real time battles. The finer points may be lost on anyone not already invested, but the game will feature robots from across the nearly 40-year old mecha series' history, including from the most recent anime series, Iron Blooded Orphans. No release date is provided yet, but the game will form part of a spearhead to reintriduce Gundam to the west.
Along with more established properties such as Dark Souls III -- due on PS4, Xbox One, and PC on 12 April -- fans of Japanese games have plenty to look forward to throughout 2016.
These robo-artisans are creating Hollywood's most elaborate props
Japan's high-tech toilets are finally conquering the West
By Matt Burgess, Victoria Turk and Matt Reynolds
The best gaming keyboards for every budget
WIRED Recommends
Japan's singing, self-cleaning toilets are conquering the West
By Jack Needham


Every day that passes I am thankful for my e-Lybra bioresonance energy healing/medicine system. The success I have experienced with it ranges from helping a child with cerebral palsy to walk again after a small accident where he stopped walking ,to reducing swelling from an insect bite. Also the way the e-Lybra can rebalance on an emotional level is extraordinary. I have treated clients with chronic anxiety with incredible success. I imagine that within a year or so I am going to be very busy. The other incredible attribute the e-Lybra has...is that it can treat clients remotely...more at www.wds-global.co.uk.


Above is picture of a 100 ft Hargrave with gelcoat which is 12 years old being refinished and layered with 3 coats of high shine, high durability ceramic coating. After a 4-step restoration polish Freedom Yacht Service detailers applied the Ceramic coatings undercover at Lauderdale Marine Center in Ft lauderdale, Florida. Ceramic coatings can give a yacht's paint and gelcoat life many added years and higher gloss and clarity. Learn more today by calling Freedom Yacht Services for all your yacht refinishing needs. Learn more at http://ceramicpro.comContact us today for a Free Quote.


For 15 years, summer was a time when half my brain was always thinking about the second weekend in August, when the interPLAY Festival turn a busy vehicular thoroughfare into a bustling performing arts festival. I was a long-time volunteer with the organization that ran the event and eventually grew into Events Wood Buffalo.
From 1990 to 2013, interPLAY was an essential and anticipated element of Fort McMurray summers. Unfortunately, hard times fell on Events Wood Buffalo and the interPLAY Festival joined several other signature events in the celebrations graveyard.
I don't miss the stress of organizing a festival of interPLAY's magnitude. It was stress that I welcomed and embraced in my younger years, which I avoid at all costs now that I'm almost 50. I miss the people and I miss the magic that was created when tents went up along Franklin Avenue and street performers began gathering crowds.
Last week, one of the legendary performers of interPLAYs gone by reached out. Dr. John Roberts appeared on the scene in about 2002, showing up out of the blue wanting to busk. He was rather insistent so we gave him a spot on the fringes of the festival site. He proceeded to hypnotize people en masse and gathered huge audiences throughout the 3-day festival. The following year we gave him a venue of his own, the outdoor amphitheatre (where Jubilee Plaza is now), and he gathered some of the biggest crowds we had ever seen and sold out late night adult-oriented indoor shows. He is the all-time box office king of interPLAY.
Dr. John Roberts fell off the map after his last visit to interPLAY in 2004. He became quite ill, unbeknownst to any of us, and was unable to work. He is much better 12 years later, and looking great.
I ran into another legend of interPLAY a few weeks back when I was doing a live painting event at Brett Wilson's Garden Party in Calgary. Clark Robertson, a.k.a. That Don Cherry Guy, was working the crowd, making people laugh and posing for hundreds of pictures. It's amazing how he has turned this characterization of one of our iconic sports/media celebrities into a great entertainment element for events.
Clark always had a knack for crowds. I always associate his performances at the 1998 interPLAY with the scaling up of the festival. He gathered huge crowds that year and the festival began to really take off.
The interPLAY Festival was a place for street performers, buskers, shopping, theatre, dance, art and music. It had a little bit of everything. Over the years that I was involved we had some amazing acts and unforgettable moments. We also had a great team of volunteers and paid professionals that turned the street into a marvellous oasis of fun every single summer.
My one regret, if I can be allowed one, is that it no longer happens. I wish in my heart of hearts that it was still alive so that I could attend and enjoy as a patron of the arts and a fan of all the disciplines it featured.


Rose Gold Side Table Copper On Small Post Modern Stainless Steel Rose Gold Small Round Coffee Table Minimalist Corner And A Jpg 640×640 All Side In Small Rose Gold Side Table 103005 1 1800x Jpg V 1519073983 All Small Rose Gold Side Table Chill Small Rose Gold Side Table For Faceted Rose Gold Side Table1 At Small Table Small Tables Side At Rose Gold Table Marble Table Gold Or Small Rose Side S L300 In Small Rose Gold Side Table Small Gold Side Table Coffee Tables Rose And Black Glass Like Small Rose Gold Side Table And Marble Round Metal Designs Kitchen Inspiring By Tables For Living Go 728×546 Within Rose Gold Side Table Lamps And Glass Nz Small Uk Anodised Aluminium Super Matt Oak Kitchen Glamorous Punt Clippings By S Like Rose Gold Accent Table Medium Size Of Side End Charming Trim Small In Rose Gold Side Table Uk Nz Bedside Lamps Glass Legend Modern Dining And Coffee Kitchen Engaging Top Coast Small Circular Within Small Gold Side Table Full Size Of Glass Black And Coffee Tables Rose Kitchen Pretty Or Rose Gold Side Table Target Marble Small Uk White And Metal Round Accent Contemporary Style Kitchen Remarkable Accen 728×549 With For Small Rose Gold Side Table Gold Metal Side Tables Low Glass Table Small Round White And Coffee Silver End Wood Brushed In Rose Small White Coffee Table With Shelf Random Rose Gold Side Small Gold Side Table Short Accent Tables Top Furniture Black With Drawer Gallery Rose At .
On this website we recommend many designs abaout Small Rose Gold Side Table that we have collected from various sites. raeumen.org that we have collected from various sites, and of course what we recommend is the most excellent of image for Small Rose Gold Side Table. If you like the design on our website, please do not hesitate to visit again and get inspiration from all the houses in the design of our web design.


The author lives in Oak Park.
C. J. Hawking is pastor of Euclid Avenue United Methodist Church in Oak Park and is executive director of the faith-based workers' rights group Chicago Arise.
This history focuses on the bitterly contested labor conflict in the early 1990s at the A.E. Staley corn processing plant in Decatur, Illinois, where workers waged one of the most hard-fought struggles in recent labor history. Originally family-owned, A.E. Staley was bought out by the multinational conglomerate Tate and Lyle, which immediately launched a full-scale assault on its union workforce. Allied Industrial Workers Local 837 responded by educating and mobilizing its members, organizing strong support from the religious and black communities, building a national and international solidarity movement, and engaging in nonviolent civil disobedience at the plant gates. This book reveals the workers' innovative tactics, such as work-to-rule and solidarity committees, that inform and strengthen today's labor movement.


Due date - you might have heard this term a thousand times from many women around you when they talk about pregnancy. Due date is simply an assumed date of delivery or the day when you expect your sweet little baby to arrive in this world.
Although it is only an estimate, the due date is calculated by adding 280 days (40 weeks) to the first day of last menstrual period. Here, we are assuming a 28 day cycle, which may vary as per the length of menstrual cycle. One also needs to understand that the menstrual period and ovulation are counted as the first two weeks of pregnancy. If one delivers on the due date, the baby is actually only 38 weeks old, not 40. Use our Due Date Calculator to find your baby's expected birth date!


text:
pub use proto_array::CountUnrealizedFull;
use serde_derive::{Deserialize, Serialize};
use types::Checkpoint;

pub const DEFAULT_FORK_CHOICE_BEFORE_PROPOSAL_TIMEOUT: u64 = 250;

#[derive(Debug, PartialEq, Eq, Clone, Deserialize, Serialize)]
pub struct ChainConfig {
    /// Maximum number of slots to skip when importing a consensus message (e.g., block,
    /// attestation, etc).
    ///
    /// If `None`, there is no limit.
    pub import_max_skip_slots: Option<u64>,
    /// A user-input `Checkpoint` that must exist in the beacon chain's sync path.
    ///
    /// If `None`, there is no weak subjectivity verification.
    pub weak_subjectivity_checkpoint: Option<Checkpoint>,
    /// Determine whether to reconstruct historic states, usually after a checkpoint sync.
    pub reconstruct_historic_states: bool,
    /// Whether timeouts on `TimeoutRwLock`s are enabled or not.
    pub enable_lock_timeouts: bool,
    /// The max size of a message that can be sent over the network.
    pub max_network_size: usize,
    /// Number of milliseconds to wait for fork choice before proposing a block.
    ///
    /// If set to 0 then block proposal will not wait for fork choice at all.
    pub fork_choice_before_proposal_timeout_ms: u64,
    /// Number of skip slots in a row before the BN refuses to use connected builders during payload construction.
    pub builder_fallback_skips: usize,
    /// Number of skip slots in the past `SLOTS_PER_EPOCH` before the BN refuses to use connected
    /// builders during payload construction.
    pub builder_fallback_skips_per_epoch: usize,
    /// Number of epochs since finalization before the BN refuses to use connected builders during
    /// payload construction.
    pub builder_fallback_epochs_since_finalization: usize,
    /// Whether any chain health checks should be considered when deciding whether to use the builder API.
    pub builder_fallback_disable_checks: bool,
    /// When set to `true`, weigh the "unrealized" FFG progression when choosing a head in fork
    /// choice.
    pub count_unrealized: bool,
    /// When set to `true`, forget any valid/invalid/optimistic statuses in fork choice during start
    /// up.
    pub always_reset_payload_statuses: bool,
    /// Whether to apply paranoid checks to blocks proposed by this beacon node.
    pub paranoid_block_proposal: bool,
    /// Whether to strictly count unrealized justified votes.
    pub count_unrealized_full: CountUnrealizedFull,
    /// Optionally set timeout for calls to checkpoint sync endpoint.
    pub checkpoint_sync_url_timeout: u64,
    /// Whether to enable the light client server protocol.
    pub enable_light_client_server: bool,
}

impl Default for ChainConfig {
    fn default() -> Self {
        Self {
            import_max_skip_slots: None,
            weak_subjectivity_checkpoint: None,
            reconstruct_historic_states: false,
            enable_lock_timeouts: true,
            max_network_size: 10 * 1_048_576, // 10M
            fork_choice_before_proposal_timeout_ms: DEFAULT_FORK_CHOICE_BEFORE_PROPOSAL_TIMEOUT,
            // Builder fallback configs that are set in `clap` will override these.
            builder_fallback_skips: 3,
            builder_fallback_skips_per_epoch: 8,
            builder_fallback_epochs_since_finalization: 3,
            builder_fallback_disable_checks: false,
            count_unrealized: true,
            always_reset_payload_statuses: false,
            paranoid_block_proposal: false,
            count_unrealized_full: CountUnrealizedFull::default(),
            checkpoint_sync_url_timeout: 60,
            enable_light_client_server: false,
        }
    }
}

redpajama_set_name: RedPajamaGithub


Algeria's national carrier Air Algerie launched a tender on Thursday to buy 14 passenger aircraft ranging from 70 to 250 seats and two 13-20 tonne-capacity cargo jets, as it seeks to renew its fleet and cope with competition on external flights.
The north African country's airline is seeking eight 150-seat, three 250-seat and three 70-seat passenger planes, it said in a notice published in government newspaper El Moudjahid.
It set April 28 as a deadline for bids from aircraft makers.
Air Algerie, fully owned by the government, currently has a fleet of 42 passenger jets and two cargo aircraft.
Algeria's flag carrier has a monopoly on domestic routes, but faces growing competition on external flights, where its main overseas routes are to Europe and the Middle East.
Its main competitors include Air France and British Airways. Qatar Airways, Emirates and Royal Jordanian are among other foreign airlines that recently started direct services to Algiers.


text:
Επιστημονικό Έργο
Απονεύρωση του νεφρού
Interventional Therapies for Secondary and Essential Hypertension
Ερευνητικό Έργο
Κλινικό Έργο
Οργανωτικό & Διοικητικό Έργο
Το Ιατρείο
Στήλη του Ασθενούς
ΔΗΜΟΣΙΕΥΣΕΙΣΠηγή: PubMED
– ΣΥΝΟΛΟ: 441 –
Μπορείτε να βρείτε όλες τις δημοσιεύσεις στο PubMed εδώ. Ακολουθούν οι πιο πρόσφατες.
Sort By None TitleDate
Increased detection of suspected atrial fibrillation in elderly and female hypertensive patients through home blood pressure monitoring: the HOME-AF study.
Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry.
Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword.
SPRINT trial phenotypes and cardiovascular risk: The 'Marathon' of data analysis is still on.
Association of QRS narrowing with response to cardiac resynchronization therapy-a systematic review and meta-analysis of observational studies.
Management of the "notorious" refractory orthostatic hypotension: Let's think and further study droxidopa.
Cardiologist as a cardiometabolic specialist.
Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective.
Association Between Blood Pressure Variability, Cardiovascular Disease And Mortality In Type 2 Diabetes: A Systematic Review And Meta-Analysis.
Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy.
Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients With Cryptogenic Cerebral Ischemia.
Embolic strokes of undetermined source: theoretical construct or useful clinical tool?
Renal Sympathetic Denervation in Isolated Systolic Hypertension.
Predictors of Adverse Outcomes in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy: A Meta-Analysis of Observational Studies.
Current perspective on the use of calcium channel blockers to treat hypertensive patients: the role of lercanidipine.
Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
Ivabradine and metoprolol in fixed dose combination: When, why and how to use it.
Hypertension and atrial fibrillation: epidemiological data, pathogenesis and therapeutic implications.
Peritoneal dialysis as a therapeutic solution in elderly patients with cardiorenal syndrome and heart failure: A case-series report.
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries.
Primary aldosteronism: novel insights.
Incidence, characteristics and outcomes in patients with embolic stroke of undetermined source: A population-based study.
Data from the cardiac catheterization laboratories in Greece.
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
Pharmacological Management of Diabetic Nephropathy.
Sympathetic System-Related Artery Stiffness.
Assessment of arterial baroreflex sensitivity by different computational analyses of pressure wave signals alone.
Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations.
Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension.
Now That Renal Denervation Works, How Do We Proceed?
[2018 ESC/ESH Guidelines for the management of arterial hypertension].
Future anti-aldosterone agents.
Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
Association of Elevated Blood Pressure Levels with Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis: A Systematic Review and Meta-Analysis.
Orthostatic hypertension: From pathophysiology to clinical applications and therapeutic considerations.
Dual antiplatelet therapy in acute coronary syndrome after stent implantation: How short is short and how long is long?
Labile hypertension: a new disease or a variability phenomenon?
Arterial hypertension in patients under antineoplastic therapy: a systematic review.
Renal denervation - can we press the "ON" button again?
MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol.
Cardiovascular disease statistics: The Greek reality.
GLP-1 receptor agonists and cardiovascular outcome trials: An update.
[2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)].
ESH Annual Meeting 2018: Reinhold Kreutz reports on the 28th European Meeting on Hypertension and Cardiovascular Protection that took place in Barcelona, Spain, 8-11 June.
The role of Angiotensin-(1-7)/Mas axis and Angiotensin Type 2 Receptors in the Central Nervous System in Cardiovascular Disease and therapeutics: A riddle to be solved.
Lowering weight equals reduction of mortality: How far are we from the "Ithaka" of ideal weight control?
2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.
2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.
Renal resistive index in hypertensive patients.
Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?
Implementing the Proclamation of Stroke and Potentially Preventable Dementias.
Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis.
Unobserved automated office BP is similar to other clinic BP measurements: A prospective randomized study.
Hospitalisations for heart failure predict mortality in pulmonary hypertension related to congenital heart disease.
Ischemic stroke in atrial fibrillation patients: don't put the blame always on heart.
The "ethos" and the "agony" of sham-controlled trials in cardiovascular medicine.
2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.
Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future.
Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients.
The efficacy of coronary sinus reducer in patients with refractory angina-A systematic review of the literature.
2018 ESC/ESH Guidelines for the management of arterial hypertension.
Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?
European Society of Hypertension position paper on renal denervation 2018.
Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications.
"Hearts that strain": Distinguishing athlete's heart from hypertensive disease in the echo lab and beyond.
Do we need biomarkers for diabetics progressing to heart failure?
The landscape of acute pericarditis in Greece: Experience from a tertiary referral center.
Nonalcoholic fatty liver disease and hypertension: coprevalent or corelated?
Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks".
Nurse's Contribution to Alleviate Non-adherence to Hypertension Treatment.
Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis.
Impact of major earthquakes on the incidence of acute coronary syndromes - A systematic review of the literature.
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
The Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".
ConfidenHT™ System for Diagnostic Mapping of Renal Nerves.
Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH).
Critical evaluation on proper antithrombotic treatment in different groups of patients undergoing vascular surgery.
Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study.
Antithrombotic treatment in patients with acute coronary syndromes and atrial fibrillation. What is established and what is missing.
The Mediterranean and the DASH dietary patterns: Insights into their role in cardiovascular disease prevention.
Treatment Thresholds and Targets in Hypertension: Different Readings of the Same Evidence?
Azilsartan and Chlorthalidone-new Powerful Fixed dose Antihypertensive Combination.
Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
Impact of ranolazine on ventricular arrhythmias - A systematic review.
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions.
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment.
The impact of financial crisis on coronary artery disease burden in Greece.
Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension.
Biomarkers determining prognosis of atrial fibrillation ablation.
Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency.
Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis.
Blood pressure variability and cardiovascular prognosis. Many expectations but limited data.
Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up study.
Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
Anti-hypertensive treatment in peripheral artery disease.
Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
The new guidelines for hypertension: Navigating between Scylla and Charybdis of clinical practice.
Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension.
Hellenic Society of Cardiology International Congress 2017.
The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up.
Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism.
Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension.
Contrast-induced acute kidney injury: beware of the risk after coronary angiography.
Serum Uric Acid is Independently Associated with Diastolic Dysfunction in Apparently Healthy Subjects with Essential Hypertension.
Editorial: Uncontrolled Hypertension and Related Comorbidities: A Clinician's Update.
Arterial Hypertension and Health-Related Quality of Life.
Exercise and cardiovascular events: Is there any J curve relation?
Heart Rate and Blood Pressure: "Connecting the Dots" in Epidemiology and Pathophysiology.
Human Immunodeficiency Virus Infection And Hypertension. Is There a Connection?
Advanced cardiopulmonary resuscitation (CPR) in the Catheterization Laboratory: Consensus document of the Working Groups of 1) Cardiopulmonary Resuscitation/Acute Cardiac Care and 2) Hemodynamic and Interventional Cardiology, Hellenic Cardiological Society.
Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension.
Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform.
Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial.
SPYRAL HTN-OFF MED study: Renal denervation in the spiral orbits of current results and future studies.
Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.
Statins and inflammation in cardiovascular disease.
Biomarkers of atrial fibrillation in hypertension.
Air pollution and arterial hypertension. A new risk factor is in the air.
Neurocardiology: An emerging concept in a "stressed-out" world.
Ultrafiltration in heart failure: Finding the entrance.
Combination drug treatment in hypertension.
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Mediterranean diet and prognosis of first-diagnosed Acute Coronary Syndrome patients according to heart failure phenotype: Hellenic Heart Failure Study.
Should renal color Doppler ultrasonography be a routine test in newly diagnosed hypertensive patient?
Characteristics of the transRADIAL approach for coronary angiography and angioplasty in GREECE: the RADIAL-GREECE registry.
Exercise capacity and haemodynamic response among 12,327 individuals with cardio-metabolic risk factors undergoing treadmill exercise.
Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial).
Adult congenital heart disease in Greece: Preliminary data from the CHALLENGE registry.
Biomarkers associated with bleeding risk in the setting of atrial fibrillation.
Biomarkers associated with stroke risk in atrial fibrillation.
Modern management of hypertensive emergencies and urgencies: Do we need more technology, paramedics, or physicians?
Cardiovascular disease prevention strategies for type 2 diabetes mellitus.
The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
A Critical Approach of Guideline Therapeutic Recommendations for NAFLD.
Anesthetic ointment only (lidocaine/prilocaine) instead of injectable local lidocaine in trans-radial catheterization: A viable no-needle alternative.
Women in cardiology practice in a "man's world".
Left ventricular ejection fraction as therapeutic target: is it the ideal marker?
Lessons learned from the recent history of technologies for noninvasive estimation of aortic blood pressure using transfer functions and pulse wave analysis.
Successful left transradial coronary angiography in an elderly patient with dextrocardia and severe aortic stenosis.
Proximal Aortic Neck Progression: Before and After Abdominal Aortic Aneurysm Treatment.
E-health in 2017: Rebooting cardiovascular care.
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.
Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model.
Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension.
Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?
Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis.
Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots.
The Clinical Problems of Hypertension Treatment in Hemodialysis Patients.
Arterial hypertension and aortic valve stenosis: Shedding light on a common "liaison".
Cardiovascular training in 2017: Reshaping tradition to envision the future.
Finding the best ablation strategy for renal denervation: A continuing saga.
Erratum to: Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry.
Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome.
Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis.
The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?
Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Noninvasive assessment of haemodynamics in resistant hypertension: the role of the renal resistive index.
Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry.
Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Waist circumference compared with other obesity parameters as a determinant of coronary artery disease in essential hypertension: from statistics to clinical practice.
Executive summary of the joint position paper on renal denervation of the Cardiovascular and Interventional Radiological Society of Europe and the European Society of Hypertension.
Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects.
Executive Summary of the Joint Position Paper on Renal Denervation of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the European Society of Hypertension (ESH).
Initial Experience with Renal Denervation for the Treatment of Resistant Hypertension - The Utility of Novel Anesthetics and Metaiodobenzylguanidine Scintigraphy (MIBG).
Will SPRINT change my practice? SPRINT: a randomised trial of intensive versus standard blood-pressure control.
Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study.
Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
Clinical Diagnosis and Management of Resistant Hypertension.
A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients.
The impact of renal sympathetic denervation on cardiac electrophysiology and arrhythmias: A systematic review of the literature.
Chemical Renal Denervation Revisited.
Renal Sympathetic Denervation: Hibernation or Resurrection?
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease.
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?
Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
Waist circumference compared with other obesity parameters as determinants of coronary artery disease in essential hypertension: a 6-year follow-up study.
An ECG Diagnosis Only for the Cold-Hearted.
Long-term effects of multielectrode renal denervation on cardiac adaptations in resistant hypertensive patients with left ventricular hypertrophy.
SPRINT Results Are Life-Saving, Guideline-Changing, and Hypertension Research-Intensifying.
Sympathetic Nervous System Activation and Left Ventricular Hypertrophy: Reflections of the Same Portrait of Resistant Hypertension?
Metabolic syndrome, independent of its components, affects adversely cardiovascular morbidity in essential hypertensives.
Economic Evaluation Of Trimetazidine In The Management Of Chronic Stable Angina In Greece.
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT).
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN I first-in-human study using a multi-electrode ablation system.
Blood pressure reduction and control with fixed-dose combination perindopril/amlodipine: A Pan-Hellenic prospective observational study.
Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Regarding "Severe bilateral renal artery stenosis after transluminal radiofrequency ablation of renal sympathetic nerve plexus".
Effects of ventriculoarterial coupling changes on renal function, echocardiographic indices and energy efficiency in patients with acute decompensated systolic heart failure under furosemide and dopamine treatment: a comparison of three therapeutic protocols.
Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.
Extreme prolongation of sinus node recovery time in a coronary artery disease patient.
Dietary and lifestyle patterns in relation to high blood pressure in children: the GRECO study.
Microcirculation in Hypertension: An Update on Clinical Significance and Therapy.
Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.
Cardiac troponin I after carotid endarterectomy in different cardiac risk patients.
Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study.
Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy: an EnligHTN I substudy.
Predictive role of stress echocardiography before carotid endarterectomy in patients with coronary artery disease.
Non-interventional management of resistant hypertension.
Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study.
Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnoea.
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).
Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study).
The effect of percutaneous renal denervation on muscle sympathetic nerve activity in hypertensive patients: more questions than answers.
Electrical stimulation of the renal arterial nerves does not unmask the blindness of renal denervation procedure in swine.
Chemical renal denervation by vincristine: the role of the flow rate of delivery.
Evaluation of apoptosis in varicose vein disease complicated by superficial vein thrombosis.
Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom).
Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system.
Atrial fibrillation and chronic kidney disease in hypertension: a common and dangerous triad.
From SYMPLICITY HTN-3 to the renal denervation global registry: where do we stand and where should we go?
Hypertension prevalence in a representative sample of Greek adults: The Hellenic National Nutrition and Health Survey (HNNHS).
Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.
European Society of Cardiology: Cardiovascular Disease Statistics 2019.
Peripartum management of hypertension. A position paper of the ESC Council on Hypertension and the European Society of Hypertension.
Impact of increased venous pressure on kidney function and mortality in cardiovascular patients with preserved ejection fraction.
Elderly patients hospitalized for acute heart failure. The case whereas lower blood pressure is always worst!
Τ/F: 2107487482
E: kptsioufis@gmail.com
Δευτέρα & Πέμπτη: 14:00 – 21.00
Κράτηση εδώ
Ο Κωνσταντίνος Τσιούφης είναι Καθηγητής Καρδιολογίας στο Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών. Απόφοιτος του '87 με βαθμό "ΑΡΙΣΤΑ", εργάζεται στο Ιπποκράτειο Γενικό Νοσοκομείο Αθηνών με τα κύρια αντικείμενα ενασχόλησής του να είναι η υπέρταση και η επεμβατική καρδιολογία.
© 2020 Δρ. Κωνσταντίνος Τσιούφης. All Rights Reserved.
Website developed by Panagiotis Tsioufis


text:
Electronic Files
2020 Buyers Resource Guide
2021 Online Form
NPE2021 Showcase
Plastics Decorating
Home Articles CI Medical Cuts Into the Health Care Industry
CI Medical Cuts Into the Health Care Industry
by Amy Bauer, Plastics Decorating
CI Medical of Norton, MA, touts itself as the only ISO 9001:2008-certified strictly transfer pad printing company in the United States catering exclusively to the medical device industry.
Transfer pad printer CI Medical, Inc. was founded 30 years ago as Creative Imprints, Inc., with a focus primarily on the advertising specialty and sporting goods industries. However, a major shift early on set a new, prosperous course for the company into the medical device market.
Today, CI Medical of Norton, MA, touts itself as the only ISO 9001:2008-certified strictly transfer pad printing company in the United States catering exclusively to the medical device industry.
President Marc Cohen founded the company in 1985, and today he and Chief Executive Officer Clifford Garnett co-own CI Medical. When Garnett joined the company in 1989, the two crafted a business plan that identified new markets and opportunities. Chief among them: the medical device industry.
Shifting industries
Cohen had done some earlier work with Boston Scientific, which at the time was looking to outsource all of its printing requirements. "The more we looked at the medical device industry, we realized that it not only was a good market for us to pursue as it related to the growth of our business, but it also was an appropriate market as it related to the attributes transfer pad printing provides: exacting precision and unparalleled quality," Garnett said, noting that the high volumes of single-use items in this sector proved an attractive opportunity.
"All of the jobs that we were going to be involved with represented annuities to us, with constant reorders of single-use-only product lines distributed in the marketplace," he said.
Boston Scientific was integral in helping Creative Imprints, Inc. transition to what would become CI Medical, Inc. It helped the company with the steps required to become an approved vendor and meet the requirements of Total Quality Management (TQM), even sending quality engineers to the print facility to assist with the transformation, Garnett said. "They said, once you become an approved vendor for Boston Scientific, the good news is that then you can market to other medical device companies in the industry," Garnett said.
By 1995, 100 percent of CI Medical's marketing and manufacturing was geared to the medical device industry. Today, the company's customer base includes not only a number of Fortune 500 companies, but also many start-up and maturing medical device OEMs, printing on thousands of product lines, marking catheters, ports, needles, connectors, syringes, textiles, heat shrink, stainless steel and Nitinol tubes, among other components. It works with such substrates as PTFE, PE, PU, silicone, Delrin, Pebax and Nitinol, to name a few.
"The functional designs that we print on the components range from 360-degree band markers to numbers to company names and logos for passive advertising," Cohen said.
Proprietary inks
Many of the device components CI Medical works with are printed with the company's proprietary Radiopaque® inks for use within a fluoroscopy and/or X-ray environment for short-term, long-term and permanent implants.
CI Medical developed its own Radiopaque® ink lines and its related transfer pad printing techniques over a number of years of research and development, and Cohen credited Engineering Manager Bruce Mahan for fine-tuning these inks in the past few years. The inks make markings on medical devices "visible" within the body to medical professionals when viewed by X-ray or fluoroscope, allowing assessment of proper positioning and placement or identification of the particular device.
Components that utilize this ink include pacemakers and chemotherapy ports, as well as tubes, fabrics and polypropylene sheets used in stent-less and/or spinal procedures.
"The ink has taken off," Cohen described of customers' demand for the product. "We pad print literally hundreds of thousands of pacemakers and ports, along with catheters and a number of medical fabrics and devices. It turned out to be a very exciting niche which none of our competitors have."
Most recently, working with one of its suppliers, CI Medical developed a Radiopaque® ink that will adhere to silicone, one of the few substrates to which its original Radiopaque® inks don't adhere.
CI Medical at a glance
CI Medical developed its own proprietary ink line to make markings on medical devices "visible" within the body when viewed by X-ray or fluoroscope.
The small but nimble CI Medical employs 20 people at its 20,000-square-foot facility in Norton, which is midway between Boston, MA, and Providence, RI. Most employees have been with the company for 10 years or more. Its work force includes a quality department led by a quality assurance manager and dedicated quality inspectors.
The current facility was designed and built in 1998 to meet the strict requirements of the medical device industry. CI Medical maintains a bio-burden-limiting clean environment, which includes a requirement for all production personnel to wear gowns, bouffant headwear and non-latex gloves when on the production floor and handling customer product.
The company was an early adopter of ISO certification, which it first obtained in 1999. While the company at the time heard from a majority of its customers that, as a secondary tier level vendor, such a step wasn't necessary, the owners saw it as a way to improve the functional management of the business. Today, such certification is a requirement for any company working in the medical device industry.
CI Medical runs a single-shift operation that is capable of expanding as needed – to a shift and a half or double shift – depending on the current mix of production requirements. Volumes range anywhere from the production of single prototypes during product development to low-seven-figure production runs, and all volumes in between.
The company specializes in finding solutions for tough printing configurations and new, cutting-edge products. It has built its business by cultivating the trust of design engineers at the medical device OEMs and positioning its employees as problem-solvers. Much of the company's work is kept strictly confidential because it involves product lines moving through the research and development and early production stages. Confidentiality and nondisclosure agreements are utilized with CI Medical's customers to ensure everyone's understanding of the relationship between the OEM and a key vendor.
"We partner with design engineers of transfer pad printing machine manufacturers from around the world. With our vast pad printing knowledge and experience base, coupled with their machine capabilities, we have jointly designed machinery that provides printing capabilities that no other company can duplicate," Cohen said.
The company has invested in technology to create a paperless environment for its document storage and retrieval system. This not only promotes great customer service, Mahan said, but also meets clients' document retention requirements. The system also provides the backbone for CI Medical's disaster recovery program.
"CI Medical has been "cloud computing" for years, which has generated many efficiencies," he said. "These are all reasons why we attract customers within the medical device industry. We take their needs and requirements very seriously and have invested heavily throughout our history to meet them."
Singular focus
The single-industry concentration allows CI Medical to laser-focus on the skills and innovations that will be relevant to its particular customer base. As with any industry, the medical device industry has undergone changes over the years. For example, many of the OEMs moved to Ireland 15 to 20 years ago to take advantage of low labor costs and government-backed tax incentives, as well as a highly educated workforce. In the past five years, Garnett said, many of those companies now have moved operations to Costa Rica for some of those same reasons.
CI Medical is somewhat insulated from the pitfalls of focusing efforts on a single industry, its owners noted. "Every once in a while, we'll bolt up at 3 a.m. realizing that we're fully concentrated in one industry, but the thing that helps us through that sleepless night is the fact that we're so well diversified as far as not only the number of companies that we provide our services to, but more importantly the number of product lines, which are in and of themselves each an individual business opportunity for us," Garnett said.
"That grows every day, and that mix changes year to year," he said. "We start with the new design engineers at the very beginning phases of new product design, wanting to get in on the ground floor of the build. And then, as these product lines go through their life cycle, they transition out of R&D and proceed to the production side of their companies. We ride those volumes as they hopefully expand as the product line gains acceptance in the marketplace."
Also, even when economic times tighten, budgets for new product innovation in the medical device industry typically aren't adversely impacted as new product designs represent the future of the medical device OEMs, Mahan said.
Targeted market
CI Medical works with engineers from the beginning phases of design through the products' life cycle as these products transition out of R&D and proceed into production.
Several strategies are used as part of a multi-pronged marketing approach by CI Medical to target the design engineers at medical equipment manufacturers. Mahan said one of the first places engineers often go when looking to solve a design problem is the Internet. CI Medical has invested its resources in search engine optimization (SEO) strategies that ensure the CI Medical website, www.cimedical.com, appears at the top of all web results when a medical device design engineer searches key words and phrases.
Mahan said the company works with a marketing firm to ensure its web presence and search engine results are top-notch. The company's website is thorough but not overly complicated, Mahan noted, to ensure that visitors quickly can find the information they need. A "What's New" section offers updates, latest news and upcoming trade show dates, keeping content fresh and relevant.
The company exhibits at the major medical device manufacturers (MDM) and biomedical shows that are staged multiple times a year throughout the US, though Mahan said fewer new leads are coming from these shows in recent years. Now, the company's participation is more about maintaining and solidifying current relationships.
Cohen and Mahan also spend time throughout the year traveling to visit current and potential clients to offer one-on-one attention. They hold "brown bag" sessions over lunches and will present samples of CI Medical's work on different challenging substrates.
"The samples not only demonstrate the quality of our printing process, but also the superior adhesion we achieve," Mahan said. "We may have an audience of two, or we may have an audience of 10. Generally, you've only got that one shot to show them that you know what you're talking about and that you can satisfy their requirements and potentially meet their future needs. A lot of times, they don't have a need at that point, but you want to make sure that when the need arises, you're the first one they think of."
By tapping into the design engineers with whom CI Medical already has established relationships and expanding through word of mouth recommendations, the company has grown its contacts. "Once you help an engineer in a problem-solving situation, you've got a friend for life," Mahan noted.
CI Medical has won several quality awards from its customers, as well as dock-to-stock privileges on a number of product lines that it prints for customers. Exploring new ways CI Medical can work to enhance the relationship with its OEM customer base always is foremost in managers' thought process.
As an example, a number of customers have instituted a Kanban relationship with CI Medical. Kanban is a system to control the logistical supply chain from a production point of view. CI Medical has embraced this concept and eagerly participates in this type of program to solidify its relationships with OEMs.
"Medical device design engineers continually are pushing the envelope on developing specialty substrates that allow surgical instruments to perform in a precise fashion. Fortunately, one of the main attributes that most of these substrates possess is the fact that nothing adheres to the surface," he said. "When it is determined in the design cycle that functional markings are required on the device, they access our technology in order to achieve success."
Future growth
Cohen said he is proud of the positive feedback the company receives from its clients. He said those who visit the company on-site are particularly complimentary.
"They walk away extremely impressed with what they see from a company that's typically much smaller than the company that they work for," he said. "It gives us positive feedback that we're doing things the right way."
He said the company always is open to new innovations and encourages its employees to be as responsive as possible to client needs. Managers are in many cases empowered to make decisions on the spot, rather than having to wait for management meetings or other lengthier processes for approvals.
"We're a service company," Cohen said. "When a customer comes in with a request, we're never asking, 'Why?' Instead, we're always asking, 'How high?' "
"It takes years to perfect the elements that go into the transfer pad printing process," Cohen said, "and we pride ourselves on being able to achieve levels of quality that are superior to anyone else who tries to perform this printing technique."
2015 Jan/Feb
Previous articleSonics to Introduce e-Press Touch
Next articleAmerica Makes Announces Project Call
20 Years of Plastics Decorating Magazine
The Price of Printing – In-House vs. Custom Decoration for Plastic Parts
Raising a Plastic Glass to Customization: GORIGHT Takes Drinkware to New Levels
785.271.5801 | publish@petersonpublications.com
© 2020 - All Rights Reserved - Peterson Publications


Two Palo Alto University doctoral students were awarded a research grant by the American Psychology-Law Society (APA Division 41), for research on psycholegal issues related to diversity.
Marissa Vasquez and Sierra Shumate, both students in the Ph.D Clinical Psychology program, submitted their project titled: A Spanish Translation of a New Malingering-Detection Measure of PTSD. The goal of their research project is to establish a standardized, Spanish-translated measure for malingered Posttraumatic Stress Disorder (PTSD) detection in order to increase available forensic psychological measures for Hispanic/Latino populations.
The competition for this award is high, with only five given annually.
"The quality of the funded proposals is very strong and includes research that makes significant advances to the field of psychology and law, especially in the area of diversity." stated Christopher L. Bishop, Psy.D., Co-Chair of the Diversity Research Award subcommittee of the Minority Affairs Committee.


text:
Eritrea Detains Dozens Of Christians
Christian Persecution » Africa » Eritrea Detains Dozens Of Christians
By Stefan J. Bos, Special Correspondent Worthy News
(Worthy News) - Dozens of Christians have been detained in Eritrea in the latest government crackdown on devoted believers, advocacy representatives said Friday.
Rights activists told Worthy News that 45 people were taken into custody at Christian gatherings in Eritrea's capital city, Asmara, in April and June alone.
Some 15 Christians were reportedly arrested as they attended a worship service in a home in the Mai Chehot area of Asmara in April. "They were initially detained in a local police station for several days. Before being transported to Mai Serwa Prison, which is infamous for its inhumane conditions, " confirmed rights organization Christian Solidarity Worldwide (CSW).
The second group of 30 people, which included some non-Christians, was reportedly arrested at the wedding of a Christian couple during the last week of June.
This group was reportedly taken to the Second Police Station, known locally as Kalai Medeber, according to Christians familiar with the situation.
Authorities are due to defend the crackdown saying those detained were arrested for breaking coronavirus restrictions. But Christians called the reaction heavy-handed.
CSW also expressed concern that the detentions come "amidst increasing concerns about the potentially deadly impact of any outbreak" of the coronavirus disease COVID-19 "in Eritrea's extensive and overcrowded" prison system.
"Tens of thousands of Eritreans are currently detained without charge or trial in life-threatening conditions in more than 300 sites across the country. Among those incarcerated are prisoners of conscience, some of whom have been detained for decades on account of their political views or religious beliefs," the group added.
"Conditions in these facilities are unsanitary and unsatisfactory. Detention facilities include shipping containers, underground cells, and the open air in the desert, and access to medical attention is insufficient and often withheld as punishment."
PERVASIVE CONTROL
CSW's Chief Executive Mervyn Thomas said: "It is clear that the Eritrean government views the COVID-19 lockdown as a means of increasing its already pervasive control of society. Instead of supporting its citizens during this difficult time, it is extorting their finances, reportedly preventing the flow of food to malnourished communities".
Thomas noted that authorities "even closed down health facilities in the Southern Red Sea region. These closures, along with the 2019 seizures of Catholic healthcare centers, have deprived the most vulnerable of access to medical assistance during an unprecedented global pandemic."
He has also demanded "the immediate and unconditional release. of every prisoner of conscience, and low-risk and vulnerable detainees in light of the COVID-19 pandemic."
Thomas said CSW had urged the United Nations Human Rights Council "to ensure continued monitoring of the country's deteriorating human rights crisis by renewing the mandate of the Special Rapporteur on Eritrea."
President Isaias Afwerki has governed the Eastern African nation with an iron fist since it became an independent country in 1993.
SOLE PARTY
His People's Front for Democracy and Justice (PFDF) is the sole political party. Presidential elections scheduled for 1997 never happened while a constitution ratified in the same year has never been implemented.
Under his rule, Eritrea's government banned groups seen as a threat to his power base. Those forbidden to gather are people not affiliated with the Catholic, Evangelical Lutheran, or Orthodox Christian denominations and Sunni Islam.
Christians claim authorities have launched a campaign of arrests targeting unapproved denominations and groups in the Eastern African nation of 6-million people.
Additionally, Christian converts from a Muslim background or an Orthodox background reportedly face harsh mistreatment from their families and communities.
Categories Africa, Christian Persecution, Eritrea Tags Africa, Christian, coronavirus, covid-19, Eritrea, EU, healthcare, Human Rights, ISIS, Islam, Media, Muslim, News, NSA, Police, sunni, United Nations, virus, Worthy News Post navigation
Turkey Expels Foreign Christians In Crackdown
UK Appeals Court: Christian adoption agency cannot refuse placements with same-sex couples when it works on behalf of local government authorities
US: Only 'a few weeks left' to save Iran nuclear deal, we're eyeing 'other options'
Hungary Supports Kazakhstan's Crackdown On Protesters
US Embassy in Baghdad targeted by multiple rockets
Eleven Oath Keepers including leader charged with seditious conspiracy in Jan. 6 riot


Rwanda is a poor rural country with about 90% of the population engaged in (mainly subsistence) agriculture. It is the most densely populated country in Africa; landlocked with few natural resources and minimal industry. Primary foreign exchange earners are coffee and tea. The 1994 genocide decimated Rwanda's fragile economic base, severely impoverished the population, particularly women, and eroded the country's ability to attract private and external investment. However, Rwanda has made substantial progress in stabilizing and rehabilitating its economy to pre-1994 levels, although poverty levels are higher now. GDP has rebounded and inflation has been curbed. Export earnings, however, have been hindered by low beverage prices, depriving the country of much needed hard currency. Despite Rwanda's fertile ecosystem, food production often does not keep pace with population growth, requiring food imports. Rwanda continues to receive substantial aid money and was approved for IMF-World Bank Heavily Indebted Poor Country (HIPC) initiative debt relief in late 2000. Kigali's high defense expenditures have caused tension between the government and international donors and lending agencies. An energy shortage and instability in neighboring states may slow growth in 2005, while the lack of adequate transportation linkages to other countries continues to handicap export growth.